Therapeutic targets: MTOR and related pathways

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The mammalian target of rapamycin (mTOR) is a key protein kinase in the phosphatidylinositol 3-kinase (PI3K)/Akt pathway.
• mTOR plays a critical role in regulating malignant cell growth, making it a significant target for cancer therapy.

Purpose of the Study:

• To review the role of mTOR in cancer.
• To discuss current mTOR inhibitors in clinical trials.
• To summarize preclinical and clinical findings on mTOR inhibitors.

Main Methods:

• Review of preclinical studies on mTOR inhibitor sensitivity.
• Analysis of clinical trial data for mTOR inhibitors.
• Evaluation of safety and efficacy of mTOR inhibitors in cancer patients.

Main Results:

• Several mTOR inhibitors, including rapamycin, temsirolimus, everolimus, and AP23573, are under clinical investigation.
• Preclinical data suggest sensitivity to mTOR inhibitors may be linked to PI3K pathway activation or specific protein expressions.
• Clinical trials demonstrate that mTOR inhibitors are generally well-tolerated and can lead to stable disease or tumor regression.

Conclusions:

• mTOR inhibitors represent a promising class of anticancer agents.
• Further research is needed to optimize treatment schedules, patient selection, and combination strategies for mTOR inhibitors.